Semin Neurol 2019; 39(05): 560-569
DOI: 10.1055/s-0039-1688978
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Diabetic Neuropathy

Elina Zakin
1   Division of Neuromuscular Medicine, Department of Neurology, NYU Langone School of Medicine, New York, New York
Rory Abrams
2   Division of Neuromuscular Medicine, Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, New York
David M. Simpson
2   Division of Neuromuscular Medicine, Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, New York
› Author Affiliations
Further Information

Publication History

Publication Date:
22 October 2019 (online)


Diabetes mellitus is becoming increasingly common worldwide. As this occurs, there will be an increase in the prevalence of known comorbidities from this disorder of glucose metabolism. One of the most disabling adverse comorbidities is diabetic neuropathy. The most common neuropathic manifestation is distal symmetric polyneuropathy, which can lead to sensory disturbances, including diminished protective sense, making patients prone to foot injuries. However, focal, multifocal, and autonomic neuropathies are also common. Diabetic nerve pain and Charcot osteoarthropathy are advanced neuropathic conditions that portend a severe deterioration in quality of life. To combat these symptoms, along with glycemic control and establishment of health care systems to educate and support patients with the complexities of diabetes, there are pharmacologic remedies to ameliorate the neurologic symptoms. Several guidelines and review boards generally recommend the use of tricyclic antidepressants, serotonin/norepinephrine-reuptake inhibitors, α-2-delta ligands, and anticonvulsants as medications to improve painful diabetic neuropathy and quality of life.

  • References

  • 1 World Health Organization. Global report on diabetes. Geneva, Switzerland. 2016 . Available at: . Accessed April 29, 2019
  • 2 Ogurtsova K, da Rocha Fernandes JD, Huang Y. , et al. IDF diabetes atlas: global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract 2017; 128: 40-50
  • 3 Prevention CfDCa. National Diabetes Statistics Report, 2017. Atlanta, GA: Centers for Disease Control and Prevention, US Department of Health and Human Services; 2017
  • 4 Papatheodorou K, Banach M, Bekiari E, Rizzo M, Edmonds M. Complications of Diabetes 2017. J Diabetes Res 2018; 2018: 3086167
  • 5 Dyck PJ, Kratz KM, Karnes JL. , et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology 1993; 43 (04) 817-824
  • 6 Barrett AM, Lucero MA, Le T, Robinson RL, Dworkin RH, Chappell AS. Epidemiology, public health burden, and treatment of diabetic peripheral neuropathic pain: a review. Pain Med 2007; 8 (Suppl. 02) S50-S62
  • 7 Iqbal Z, Azmi S, Yadav R. , et al. Diabetic peripheral neuropathy: epidemiology, diagnosis, and pharmacotherapy. Clin Ther 2018; 40 (06) 828-849
  • 8 Kaku M, Vinik A, Simpson DM. Pathways in the diagnosis and management of diabetic polyneuropathy. Curr Diab Rep 2015; 15 (06) 609
  • 9 Hébert HL, Veluchamy A, Torrance N, Smith BH. Risk factors for neuropathic pain in diabetes mellitus. Pain 2017; 158 (04) 560-568
  • 10 Jaiswal M, Divers J, Dabelea D. , et al. Prevalence of and risk factors for diabetic peripheral neuropathy in youth with type 1 and type 2 diabetes: SEARCH for Diabetes in Youth Study. Diabetes Care 2017; 40 (09) 1226-1232
  • 11 Sadosky A, Schaefer C, Mann R. , et al. Burden of illness associated with painful diabetic peripheral neuropathy among adults seeking treatment in the US: results from a retrospective chart review and cross-sectional survey. Diabetes Metab Syndr Obes 2013; 6: 79-92
  • 12 Gordois A, Scuffham P, Shearer A, Oglesby A, Tobian JA. The health care costs of diabetic peripheral neuropathy in the US. Diabetes Care 2003; 26 (06) 1790-1795
  • 13 McGill M, Blonde L, Chan JCN, Khunti K, Lavalle FJ, Bailey CJ. ; Global Partnership for Effective Diabetes Management. The interdisciplinary team in type 2 diabetes management: challenges and best practice solutions from real-world scenarios. J Clin Transl Endocrinol 2016; 7: 21-27
  • 14 Gregory NS, Seley JJ, Dargar SK, Galla N, Gerber LM, Lee JI. Strategies to prevent readmission in high-risk patients with diabetes: the importance of an interdisciplinary approach. Curr Diab Rep 2018; 18 (08) 54
  • 15 Archer AG, Watkins PJ, Thomas PK, Sharma AK, Payan J. The natural history of acute painful neuropathy in diabetes mellitus. J Neurol Neurosurg Psychiatry 1983; 46 (06) 491-499
  • 16 Vinik A, Casellini C, Nevoret ML. Diabetic neuropathies. In: De Groot LJ, Chrousos G, Dungan K. , et al, eds. Endotext. South Dartmouth, MA:, Inc; 2000
  • 17 Tesfaye S, Boulton AJ, Dyck PJ. , et al; Toronto Diabetic Neuropathy Expert Group. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care 2010; 33 (10) 2285-2293
  • 18 Dyck PJ, Albers JW, Andersen H. , et al; Toronto Expert Panel on Diabetic Neuropathy. Diabetic polyneuropathies: update on research definition, diagnostic criteria and estimation of severity. Diabetes Metab Res Rev 2011; 27 (07) 620-628
  • 19 Vinik A. The approach to the management of the patient with neuropathic pain. J Clin Endocrinol Metab 2010; 95 (11) 4802-4811
  • 20 Gibbons CH, Goebel-Fabbri A. Microvascular complications associated with rapid improvements in glycemic control in diabetes. Curr Diab Rep 2017; 17 (07) 48
  • 21 Sharma KR, Cross J, Farronay O, Ayyar DR, Shebert RT, Bradley WG. Demyelinating neuropathy in diabetes mellitus. Arch Neurol 2002; 59 (05) 758-765
  • 22 Freeman R. Not all neuropathy in diabetes is of diabetic etiology: differential diagnosis of diabetic neuropathy. Curr Diab Rep 2009; 9 (06) 423-431
  • 23 Jeffcoate WJ. Charcot foot syndrome. Diabet Med 2015; 32 (06) 760-770
  • 24 Nongmaithem M, Bawa AP, Pithwa AK, Bhatia SK, Singh G, Gooptu S. A study of risk factors and foot care behavior among diabetics. J Family Med Prim Care 2016; 5 (02) 399-403
  • 25 Rogers LC, Frykberg RG, Armstrong DG. , et al. The Charcot foot in diabetes. Diabetes Care 2011; 34 (09) 2123-2129
  • 26 Vinik AI, Nevoret ML, Casellini C, Parson H. Diabetic neuropathy. Endocrinol Metab Clin North Am 2013; 42 (04) 747-787
  • 27 Fernyhough P, Roy Chowdhury SK, Schmidt RE. Mitochondrial stress and the pathogenesis of diabetic neuropathy. Expert Rev Endocrinol Metab 2010; 5 (01) 39-49
  • 28 Verkhratsky A, Fernyhough P. Calcium signalling in sensory neurones and peripheral glia in the context of diabetic neuropathies. Cell Calcium 2014; 56 (05) 362-371
  • 29 Sifuentes-Franco S, Pacheco-Moisés FP, Rodríguez-Carrizalez AD, Miranda-Díaz AG. The role of oxidative stress, mitochondrial function, and autophagy in diabetic polyneuropathy. J Diabetes Res 2017; 2017: 1673081
  • 30 Javed S, Alam U, Malik RA. Burning through the pain: treatments for diabetic neuropathy. Diabetes Obes Metab 2015; 17 (12) 1115-1125
  • 31 Llewelyn JG, Gilbey SG, Thomas PK, King RH, Muddle JR, Watkins PJ. Sural nerve morphometry in diabetic autonomic and painful sensory neuropathy. A clinicopathological study. Brain 1991; 114 (Pt 2): 867-892
  • 32 Baron R, Hans G, Dickenson AH. Peripheral input and its importance for central sensitization. Ann Neurol 2013; 74 (05) 630-636
  • 33 O'Brien T, Karem J. Relative sensory sparing in the diabetic foot implied through vibration testing. Diabet Foot Ankle 2013;4. DOI: 10.3402/dfa.v4i0.21278
  • 34 Bourcier ME, Ullal J, Parson HK. , et al. Diabetic peripheral neuropathy: how reliable is a homemade 1-g monofilament for screening?. J Fam Pract 2006; 55 (06) 505-508
  • 35 Wang F, Zhang J, Yu J. , et al. Diagnostic accuracy of monofilament tests for detecting diabetic peripheral neuropathy: a systematic review and meta-analysis. J Diabetes Res 2017; 2017: 8787261
  • 36 Zochodne DW. Clinical features of diabetic polyneuropathy. Handb Clin Neurol 2014; 126: 23-30
  • 37 Fathy C, Patel S, Sternberg Jr P, Kohanim S. Disparities in adherence to screening guidelines for diabetic retinopathy in the United States: a comprehensive review and guide for future directions. Semin Ophthalmol 2016; 31 (04) 364-377
  • 38 Tuttolomondo A, Maida C, Pinto A. Diabetic foot syndrome as a possible cardiovascular marker in diabetic patients. J Diabetes Res 2015; 2015: 268390
  • 39 Balcioğlu S, Arslan U, Türkoğlu S, Ozdemir M, Cengel A. Heart rate variability and heart rate turbulence in patients with type 2 diabetes mellitus with versus without cardiac autonomic neuropathy. Am J Cardiol 2007; 100 (05) 890-893
  • 40 Pop-Busui R, Evans GW, Gerstein HC. , et al; Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of cardiac autonomic dysfunction on mortality risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care 2010; 33 (07) 1578-1584
  • 41 Kaku M, Simpson DM. HIV neuropathy. Curr Opin HIV AIDS 2014; 9 (06) 521-526
  • 42 de Freitas MR. Infectious neuropathy. Curr Opin Neurol 2007; 20 (05) 548-552
  • 43 Collins MP, Hadden RD. The nonsystemic vasculitic neuropathies. Nat Rev Neurol 2017; 13 (05) 302-316
  • 44 Tavee J, Zhou L. Small fiber neuropathy: a burning problem. Cleve Clin J Med 2009; 76 (05) 297-305
  • 45 Gibbons CH, Griffin JW, Polydefkis M. , et al. The utility of skin biopsy for prediction of progression in suspected small fiber neuropathy. Neurology 2006; 66 (02) 256-258
  • 46 Lauria G, Bakkers M, Schmitz C. , et al. Intraepidermal nerve fiber density at the distal leg: a worldwide normative reference study. J Peripher Nerv Syst 2010; 15 (03) 202-207
  • 47 Ebenezer GJ, Hauer P, Gibbons C, McArthur JC, Polydefkis M. Assessment of epidermal nerve fibers: a new diagnostic and predictive tool for peripheral neuropathies. J Neuropathol Exp Neurol 2007; 66 (12) 1059-1073
  • 48 Dworkin RH, Turk DC, Revicki DA. , et al. Development and initial validation of an expanded and revised version of the Short-form McGill Pain Questionnaire (SF-MPQ-2). Pain 2009; 144 (1–2): 35-42
  • 49 Feldman EL, Stevens MJ, Thomas PK, Brown MB, Canal N, Greene DA. A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care 1994; 17 (11) 1281-1289
  • 50 Zelman DC, Gore M, Dukes E, Tai KS, Brandenburg N. Validation of a modified version of the Brief Pain Inventory for painful diabetic peripheral neuropathy. J Vasc Nurs 2005; 23 (03) 97-104
  • 51 Krause SJ, Backonja MM. Development of a neuropathic pain questionnaire. Clin J Pain 2003; 19 (05) 306-314
  • 52 Bouhassira D, Attal N, Fermanian J. , et al. Development and validation of the Neuropathic Pain Symptom Inventory. Pain 2004; 108 (03) 248-257
  • 53 Vileikyte L, Peyrot M, Bundy C. , et al. The development and validation of a neuropathy- and foot ulcer-specific quality of life instrument. Diabetes Care 2003; 26 (09) 2549-2555
  • 54 Smith SC, Lamping DL, Maclaine GD. Measuring health-related quality of life in diabetic peripheral neuropathy: a systematic review. Diabetes Res Clin Pract 2012; 96 (03) 261-270
  • 55 Robertson P, Davis C, Larsen J, Stratta R, Sutherland DE. ; American Diabetes Association. Pancreas transplantation in type 1 diabetes. Diabetes Care 2004; 27 (Suppl. 01) S105
  • 56 Boyd AL, Barlow PM, Pittenger GL, Simmons KF, Vinik AI. Topiramate improves neurovascular function, epidermal nerve fiber morphology, and metabolism in patients with type 2 diabetes mellitus. Diabetes Metab Syndr Obes 2010; 3: 431-437
  • 57 Smith AG, Russell J, Feldman EL. , et al. Lifestyle intervention for pre-diabetic neuropathy. Diabetes Care 2006; 29 (06) 1294-1299
  • 58 Spallone V. Management of painful diabetic neuropathy: guideline guidance or jungle?. Curr Diab Rep 2012; 12 (04) 403-413
  • 59 Hossain SM, Hussain SM, Ekram AR. Duloxetine in painful diabetic neuropathy: a systematic review. Clin J Pain 2016; 32 (11) 1005-1010
  • 60 Dworkin RH, O'Connor AB, Audette J. , et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc 2010; 85 (3, Suppl): S3-S14
  • 61 Centre for Clinical Practice at NICE (UK). Neuropathic pain: the pharmacological management of neuropathic pain in adults in non-specialist settings. London: National Institute for Health and Care Excellence, (UK); 2013
  • 62 Raskin J, Smith TR, Wong K. , et al. Duloxetine versus routine care in the long-term management of diabetic peripheral neuropathic pain. J Palliat Med 2006; 9 (01) 29-40
  • 63 Bril V, England J, Franklin GM. , et al. Evidence-based guideline: treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. PM R 2011; 3 (04) 345-352 , 352.e1–352.e21
  • 64 Dogra S, Beydoun S, Mazzola J, Hopwood M, Wan Y. Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo-controlled study. Eur J Pain 2005; 9 (05) 543-554
  • 65 Rull JA, Quibrera R, González-Millán H, Lozano Castañeda O. Symptomatic treatment of peripheral diabetic neuropathy with carbamazepine (Tegretol): double blind crossover trial. Diabetologia 1969; 5 (04) 215-218
  • 66 Jose VM, Bhansali A, Hota D, Pandhi P. Randomized double-blind study comparing the efficacy and safety of lamotrigine and amitriptyline in painful diabetic neuropathy. Diabet Med 2007; 24 (04) 377-383
  • 67 Eisenberg E, Lurie Y, Braker C, Daoud D, Ishay A. Lamotrigine reduces painful diabetic neuropathy: a randomized, controlled study. Neurology 2001; 57 (03) 505-509
  • 68 Vinik AI, Tuchman M, Safirstein B. , et al. Lamotrigine for treatment of pain associated with diabetic neuropathy: results of two randomized, double-blind, placebo-controlled studies. Pain 2007; 128 (1–2): 169-179
  • 69 Silver M, Blum D, Grainger J, Hammer AE, Quessy S. Double-blind, placebo-controlled trial of lamotrigine in combination with other medications for neuropathic pain. J Pain Symptom Manage 2007; 34 (04) 446-454
  • 70 Raskin P, Donofrio PD, Rosenthal NR. , et al; CAPSS-141 Study Group. Topiramate vs placebo in painful diabetic neuropathy: analgesic and metabolic effects. Neurology 2004; 63 (05) 865-873
  • 71 Kremer M, Salvat E, Muller A, Yalcin I, Barrot M. Antidepressants and gabapentinoids in neuropathic pain: Mechanistic insights. Neuroscience 2016; 338: 183-206
  • 72 Vinik A, Emir B, Cheung R, Whalen E. Relationship between pain relief and improvements in patient function/quality of life in patients with painful diabetic peripheral neuropathy or postherpetic neuralgia treated with pregabalin. Clin Ther 2013; 35 (05) 612-623
  • 73 Capsaicin Study Group. Effect of treatment with capsaicin on daily activities of patients with painful diabetic neuropathy. Diabetes Care 1992; 15 (02) 159-165
  • 74 The Capsaicin Study Group. Treatment of painful diabetic neuropathy with topical capsaicin. A multicenter, double-blind, vehicle-controlled study. Arch Intern Med 1991; 151 (11) 2225-2229
  • 75 Peppin JF, Majors K, Webster LR, Simpson DM, Tobias JK, Vanhove GF. Tolerability of NGX-4010, a capsaicin 8% patch for peripheral neuropathic pain. J Pain Res 2011; 4: 385-392
  • 76 Simpson DM, Brown S, Tobias J. ; NGX-4010 C107 Study Group. Controlled trial of high-concentration capsaicin patch for treatment of painful HIV neuropathy. Neurology 2008; 70 (24) 2305-2313
  • 77 Baron R, Mayoral V, Leijon G, Binder A, Steigerwald I, Serpell M. Efficacy and safety of combination therapy with 5% lidocaine medicated plaster and pregabalin in post-herpetic neuralgia and diabetic polyneuropathy. Curr Med Res Opin 2009; 25 (07) 1677-1687
  • 78 O'Connor AB, Dworkin RH. Treatment of neuropathic pain: an overview of recent guidelines. Am J Med 2009; 122 (10, Suppl): S22-S32
  • 79 Cepeda MS, Coplan PM, Kopper NW, Maziere JY, Wedin GP, Wallace LE. ER/LA opioid analgesics REMS: overview of ongoing assessments of its progress and its impact on health outcomes. Pain Med 2017; 18 (01) 78-85
  • 80 Schwartz S, Etropolski M, Shapiro DY. , et al. Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial. Curr Med Res Opin 2011; 27 (01) 151-162
  • 81 Vinik AI, Shapiro DY, Rauschkolb C. , et al. A randomized withdrawal, placebo-controlled study evaluating the efficacy and tolerability of tapentadol extended release in patients with chronic painful diabetic peripheral neuropathy. Diabetes Care 2014; 37 (08) 2302-2309